Veriheal

DECEMBER 28, 2021

D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted. Chronic pain. Amyotrophic lateral sclerosis (ALS). Alzheimer’s. Depression. Multiple Sclerosis. Tourette Syndrome.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Veriheal

MARCH 6, 2024

Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. The HSS found strong scientific support regarding cannabis’ medically beneficial effects for conditions like anorexia , nausea, and chronic pain.

Research and Development 64

Research and Development DEA Chronic Pain Business 64

NewsMunchies

SEPTEMBER 5, 2018

A new marijuana-derived drug to treat rare forms of severe epilepsy in children will cost about $32,500 per patient, per year. Food and Drug Administration (DEA), contains the active ingredient cannabidiol (CBD) but it does not contain psychoactive molecule THC, which generates the marijuana high.

Supply Chain 40

Supply Chain Pharmaceutical DEA Chronic Pain 40

MedicalJane

JUNE 29, 2018

Pennsylvania’s neighboring state, Maryland , has a much shorter list of qualifying medical conditions: cachexia, anorexia, wasting syndrome, severe pain or nausea or persistent muscle spasms, seizures, glaucoma, PTSD, and chronic pain. Can your current doctor “prescribe” cannabis?

Patients 83

Patients Legalization Conditions Treatment 83

The Joint Blog

JUNE 4, 2021

Those state laws allow medical marijuana to be used to treat ailments like Alzheimer’s, cancer, epilepsy, Crohn’s disease, seizures, hepatitis C and a host of others. The United States Food and Drug Administration (FDA) has only cannabis use to treat two rare and severe forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome.

Conditions 32

Conditions Chronic Pain Marijuana Research and Development 32

SpeedWeed

JUNE 15, 2021

Rather than going head-to-head with other well-funded competitors in some US state auction while facing down the DEA or buying out a patient collective or two in Canada, the process was a bit simpler. The company’s medical products are whole-plant based and work—on label—for alleviating the symptoms of MS and epilepsy.

Pharmaceutical 40

Pharmaceutical Chronic Pain Epilepsy Patients 40

Cannabis Law Report

SEPTEMBER 23, 2019

26 Evidence is most substantial for nausea and vomiting associated with chemotherapy, chronic pain treatment, multiple sclerosis spasticity, and intractable seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. Cannabinoids have been assessed for chronic pain management.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40